
    
      Parallel-group, case-controlled trial was conducted from September 2015 to November 2017. All
      the patients who referred for video-fluoroscopic-swallowing study were screened.

      Based on the pre-emptive evaluation, high-risky patients were allocated to iohexol
      (Omnipaque)-used video-fluoroscopic-swallowing study and others were allocated to barium
      sulfate-used video-fluoroscopic-swallowing study.

      Statistical Package for the Social Sciences 24 was used to perform statistical analysis for
      the data. Quantitative data were presented as mean Â± standard errors.
    
  